STipe Therapeutics

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitize the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.

Contact name:

Claus Elsborg Olesen


Lyngsiesvej 18, 8230 Åbyhøj, Denmark


+45 61260035



Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 5150 0560

Copyright 2019 Danskbiotek. All rights reserved.